Introduction
The polymerase chain reaction (PCR) has been used for over a decade in the field of hematologic malignancy. It has been extensively employed in molecular cytogenetics for the detection of translocations associated with particular malignancies, often in the setting of minimal subclinical disease. The characteristic chromosomal translocation associated with follicular lymphoma, the t(14;18)(q32;q21), has been extensively studied using PCR to detect small amounts of genomic DNA with the bcl-2-lgH abnormality against a normal background [1] . The clustering of bcl-2 breakpoints on chromosome 18q21 within two main regions, the major breakpoint region (MBR) and minor cluster region (MCR) has allowed the design of primers to span the rearrangements present in approximately 70% of cases [2] . Each translocation has a unique sequence as a result of the variety of different breakpoints on the two partner chromosomes and the insertion of de novo synthesised 'N' regions, sometimes together with sequences derived from diversity regions, in the process of recombination [3] . As a result, specific clones related to individual Iymphomas may be followed in clinical samples over time.
Using the PCR, which has been estimated to detect DNA from one translocation-bearing cell among up to 10 6 normals, several observations have been made. Firstly, the great majority of patients with follicular lymphoma have Z>c/-2-IgH-bearing cells in the bone marrow at presentation [4] , even when the disease appears anatomically localised [5] . These cells generally remain detectable following conventional chemotherapy, and may be detectable for several years despite continuing clinical remission [6, 7] . The use of high dose therapy in B-cell lymphoma with ex vivo 'purged' autologous bone marrow or peripheral blood progenitor rescue has been investigated by molecular studies, the results of which have been variable. In one series the reinfusion of PCRpositive bone marrow was associated with more rapid recurrence than rescue with PCR-negative marrow [8] , but in another series with similar purging techniques the proportion of patients receiving PCR-negative marrows was much lower, although the clinical outcomes were similar [2] . The analysis of samples during follow up has also yielded variable results, with some groups reporting a close association between positive PCR results and recurrences [9] [10] [11] and others less prognostic significance. A further complicating factor has been the identification of low levels of bcl-2-lgH in the B-cell compartment of normal individuals [12, 13] . However, this situation must be distinguished from the finding of a bcl-2-lgH clone in a patient with lymphoma which had been previously been found to carry the same translocation sequence in biopsy material: the relationship between a proven lymphoma and the DNA abnormality must be demonstrated for the PCR results to have relevance. For this reason the comparison of amplification products between morphologically characteristed biopsy material and follow-up samples is critical. Direct sequencing is the method normally used in this context.
In addition to the biological uncertainties regarding the degree of association between bcl-2-lgH and the presence of lymphoma, there are practical difficulties in interpreting the studies that have been performed. Investigators have described a variety of methodologies in performing the PCR, with different primer sequences, methods of amplification and detection of amplification products, making the comparison of results from different laboratories problematic. The need for uniformity in these tests is made more pressing by proposals to pursue 'molecular remission' in the treatment of lymphoma, with decisions about further therapy being based upon the information from PCR tests. This collaborative study was undertaken in order to clarify the degree of reproducibility between laboratories.
Methods

Laboratories
A literature search was performed to identify laboratories in Europe and the US in which PCR analyses for the bcl-2-lgH were performed, and from which results of PCR studies in hematologic malignancy had been published in the literature. The principal investigators were contacted and asked to participate in the study. Those that agreed to take part were asked to specify in advance the methodology to be used in detecting translocations in the major breakpoint region o(bcl-2.
Samples
The t(14;18)-bearing cell line DoHH-2 was grown in culture at the central laboratory. Blood from five healthy donors, containing 1.5-2.5 x I0 9 mononuclear cells/1, was obtained from unused stock at the Blood Transfusion Service and screened for antibodies to hepatitis B and C, Human Immunodeficiency virus I and II and Treponema pallidum. The blood was collected with citrate/phosphate/dextrose anticoagulant and films examined to exclude Plasmodium sp. infection. Each 450 ml unit of blood was divided into five equal parts and spiked with varying numbers of DoHH-2 cells to a final concentration of 1000,100,10,1 or 0 cells/ml of whole blood. Cell dilutions were carried out in a separate laboratory to cell culture and PCR experiments. Aliquots of 10 ml were taken from each concentration and labelled by non-identifying numbers before despatch in Starstedt tubes by courier to the different laboratories. Paired samples at each dilution were sent, so that each laboratory received 10 blinded samples. The maximum transport time for samples was 36 hours and all laboratories had extracted DNA by 48 hours.
PCR methodology
Details of the different methodologies employed in the various laboratories are given inTable 1. There were variations in method including DNA extraction, PCR enzymes and thermal cyclers, numbers of cycles and detection methods for the products. The total amount of DNA analysed at each laboratory varied between 1 ug and 4 ug (median 2 ug). Although the immunoglobulin heavy chain consensus primer on chromosome 14 (5'-ACCTGAGGAGACGGTGACC-3') or a slight variant of it was used by all laboratories, there was marked heterogeneity in the bcl-2 primers used, with 13 different sequences given for primers directed at the MBR region. The majority were clustered together at the 3' end ( Figure I ). Twelve laboratories used nested or semi-nested PCR (48-70 cycles total, median 60) whilst eight used single round amplification only (30-50 cycles, median 40). In 12 cases the amplification products were detected by ethidium bromide staining of agarose gels whilst in 7 cases hybridisation of internal oligonucleotide probes was used. All laboratories included at least one negative control in each amplification run. Five laboratories reported having the DoHH-2 cell line for other purposes, although it was only growing in one of these at the time of the study.
Analysis of results
Results were forwarded to the central laboratory without knowledge of the content of the samples, and collated before individual laboratories were informed of their performance. Univariate comparisons of methodology were carried using the x 2 -test. A probability level of P = 0 05 was taken as significant.
Results
Sensitivity of detection
The proportion of positive results in the study as a whole reflected the numbers of DoHH-2 cells in the samples (Table 2, Figure 2 ). At levels of 1000 and 100 bcl-2-lgH cells per ml of blood, 92% and 88% of samples respectively were reported positive, whilst at 10 cells/ml the figure was 60% and at 1 cell/ml 38%.
Methodology and sensitivity
The centres are ranked in Table 1 according to the accuracy of the results, subdivided according to whether or not nested PCR was used (compare with Table 2 ). There was no correlation between sensitivity and the transport times, different methods of DNA extraction nor the total quantity of DNA used as template. Similarly, there was no consistent relationship between primer sequences and the results, nor with the method used for detection of amplification products.
There was a significant difference in sensitivity between nested and single round PCR at 10 cells/ml: nested PCR was positive in 79% of samples whereas single round PCR was positive in 31% (P = 0.002). At 1 cell/ml the figures were 46% and 25% (P -NS).
The difference between nested and single-round methods was further emphasised when only those 11 laboratories with no false positive results were considered. Four of six laboratories using nested amplification detected 1 cell per ml, whilst none of the five using single round amplification detected less than 100 cells per ml (P = 0.0009 at 10 cells/ml, P = 0.02 at 1 cell/ml).
False positive results
Positive amplifications were reported in 11 samples (28% of the total) from 9 laboratories in samples to which no DoHH-2 cells had been added. In all cases the amplification products were of the same size as those from positive samples, and direct sequence analysis in four cases confirmed the presence of the DoHH-2 breakpoint sequence. One laboratory using nested PCR observed an amplification product of a different size in one negative tube, but discounted this as artefactual. Three of the laboratories with false positive results had grown the DoHH-2 cell line in culture at some time previously but in only one was it being grown at the time of the study. False positive results were seen in 8 of 24 (33%) samples studied by nested PCR and 3 of 16 (19%) samples studied by single round amplification. Neither the method of processing the sample before DNA extraction nor the total amount of DNA amplified appeared to influence the false positive rate. 
Discussion
From the results obtained in this study it is clear that marked variations exist in the detection of the bcl-2-lgH in the different laboratories that perform PCR. This might have been anticipated from the various reports in the literature, but a difference in sensitivity of two logs is more than expected. Many factors might account for such variation. The factor to emerge as clearly significant from this study is the use of nested PCR, suggesting that this plays a dominant role in determining sensitivity. It is possible that methods of sample preparation, primer sequences, enzyme type, PCR machine, detection methods or other factors may also play a role, but the number of different methods for each of these would necessitate a very large study to derive useful information in a multivariate analysis. The sharp cut-off in detection at 100 cells/ml (or approximately 1 cell in 10 4 ) for single round PCR shows remarkable uniformity in those laboratories with no false positive results, suggesting that this may represent an accurate measure of the sensitivity. Similarly the consistent detection of 10 cells/ml and frequent detection of 1 cell/ml by nested PCR suggests that this is significantly more sensitive, and at this level the experiments appear to be reaching the technical limit of sensitivity in detecting as little as one copy of bcl-2-lgH DNA per reaction. A question that must be addressed in the future is whether sensitivity at this level yields useful prognostic information, or detects clones at such a low level that the biological significance is lost, as suggested by studies of the translocation in normal subjects or those in long term remission.
There are practical difficulties inherent in performing studies such as this, particularly in achieving consistency in the quality of samples received in the different laboratories, although transit times were kept to a maximum of 48 hours. In this context it is reassuring to note that the overall trend in detection of the translocation is consistent over the whole series, with the number of positive results correlating to the numbers of bcl-2-lgH cells at each dilution. This suggests that the ratio of normal to translocation-bearing cells remained roughly constant despite the effects of long distance transport.
The false positive rate is disturbing, although this effect is recognised as a potential difficulty with PCR methods. It is unlikely that the samples were contaminated at the central laboratory, firstly because strict precautions were taken to prevent this and secondly because four laboratories using highly sensitive PCR showed negative results in both normal samples. The possibility of 'background' translocations as reported in normal samples in some series is also ruled out by the product size identity and sequence analyses, which demonstrated that it was contamination by DoHH-2 DNA that was responsible for all but one of the false positives. The possibility exists of contamination by material from this cell line present in some laboratories, but the false positive rate in these laboratories did not differ from the rate in those where it had never been cultured. It seems most likely therefore that false positive results were the result of cross-contamination within the laboratories at the time the testing was performed. This is supported by the finding of a slightly higher rate in those laboratories using nested PCR, where the opportunities for contamination with amplicons are known to be greater. It is possible that this study underestimates the false positive rate, since amplified bands of different size to that expected may have been discounted by investigators knowing that a cell line had been used and that all the PCR products should be of identical size. In practice however this reflects the situation during follow-up when results from biopsy material can be compared to the sample being tested.
One clear conclusion from this study is that in order to compare results from different laboratories, and especially to determine the significance of 'molecular remission', a more uniform standard of testing is required. Until the margins of error demonstrated in this study can be narrowed, it is difficult to envisage how the results of PCR analyses may be used in the multicentre studies which will be required to evaluate prospectively interventions designed to eradicate PCR-detectable residual disease. A good case could be made for centralising the testing of samples in such studies, and in this context the advent of a more convenient and readily applicable method of quantitation such as real-time PCR [14] [15] [16] may prove to be a useful advance. Further studies such as this will be required to determine the reproducibility of the approach, and automated systems may make standardisation easier to achieve. At present it can be concluded that maximum sensitivity is achieved using nested PCR with at least 55 cycles of amplification. The methods to be used may be selected from those employed at the most successful centres in this study, namely numbers 1, 8, 9 or 11 in Table 1 .
Until now, the pursuit of maximum sensitivity has been a primary goal of many molecular studies, based upon the assumption that a more sensitive test may yield better prognostic information. There are several reasons to conclude that this may not necessarily be the case. Firstly, it is likely that the false positive rate increases as does sensitivity, whether from contamination as shown in this study, or from background translocations.
Secondly, the presence of cells bearing a lymphomarelated translocation at low levels has been demonstrated despite continued remission in several series, suggesting that a very sensitive method may detect cells whose presence does not correlate with the probability of recurrence. In view of this, a test of intermediate sensitivity may provide better information on the course of the lymphoma, and the goal of further studies by this collaborative group will be to define a method which is both reproducible and prognostic.
